OPK

OPKO Health, Inc. - Q1 2010 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2010. OPKO Health, Inc. is a specialty healthcare company focused on the discovery, development, and commercialization of pharmaceutical products, medical devices, vaccines, and diagnostic technologies. The company operates two primary segments: Pharmaceutical (including operations in Chile and Mexico) and Instrumentation (ophthalmic devices). As of May 3, 2010, the company had 255,231,867 shares of common stock outstanding.

Key Financial Metrics

Liquidity: Total cash, cash equivalents, and marketable securities stood at approximately $38.7 million as of March 31, 2010. The company has a fully drawn $12.0 million line of credit with a related party (The Frost Group) and $15.5 million in aggregate lines of credit in Chile and Mexico, of which $10.8 million remains unused.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 244% to $7.9 million, driven primarily by the inclusion of revenue from Pharma Genexx (acquired Oct 2009) and Pharmacos Exakta (acquired Feb 2010). The 2009 period reflected revenue only from the instrumentation business.
• Reduced Operating Loss: The operating loss narrowed significantly to $4.1 million from $8.6 million. This improvement was largely due to a decrease in Research and Development (R&D) expenses.
• R&D Expense Decline: R&D expenses dropped to $1.3 million from $5.7 million. The 2009 figure included significant costs associated with the shutdown of the Phase III clinical trial for bevasiranib, including patient transition and data analysis costs.
• Acquisition Activity: In February 2010, OPKO acquired Pharmacos Exakta for $3.6 million ($1.6 million cash, $2.0 million stock). This added manufacturing and distribution capabilities in Mexico.
• Debt Position: Current liabilities increased to $29.8 million from $13.0 million, primarily due to an increase in the current portion of lines of credit (from $4.3 million to $16.7 million).

Outlook, Risks, and Management Commentary

• Profitability Outlook: Management expects to incur substantial operating losses for the foreseeable future as the company continues R&D and builds commercial infrastructure. The company does not expect to become profitable in the near future.
• Liquidity Needs: While current cash resources ($38.7 million) are deemed sufficient for the next 12 months, the company will require substantial additional funding for future clinical trials, product development, and potential acquisitions. Future financing may involve equity offerings, debt, or strategic collaborations, potentially diluting shareholders.
• Key Risks:
  • Technologies are in early stages and unproven; clinical trials may fail or not satisfy FDA requirements.
  • Dependence on third-party manufacturers and collaborators.
  • Regulatory approval processes are expensive, time-consuming, and uncertain.
  • Significant concentration of ownership among directors and executive officers.
  • Exposure to foreign currency exchange rates (hedged via forward contracts).
• Unusual Items: The company recorded a $231,000 loss from investments in investees (Cocrystal Discovery, Inc.) and recognized $1.2 million in equity-based compensation expense.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $38.7 million cash position against the projected R&D and SG&A expenses for the remainder of 2010.
• Related Party Transactions: Review the terms of the $12 million line of credit with The Frost Group (11% interest, due Jan 2011) and the lease agreements with entities controlled by Dr. Frost.
• Acquisition Integration: Assess the financial performance and integration progress of the newly acquired Pharmacos Exakta and Pharma Genexx operations.
• Preferred Stock Obligations: Note the $662,000 preferred stock dividend paid in Q1 2010 and the liquidation values of Series A and Series D preferred stock.
• Derivative Exposure: Confirm the status of the $8.4 million in foreign exchange forward contracts used to hedge Chilean peso exposure.